iPSC-CAR NK therapeutic / Cytovia Therap, New York Stem Cell Foundation - LARVOL DELTA

Cytovia Therapeutics’ Scientific Leadership to Present at Upcoming Conferences (Businesswire) - "Cytovia Therapeutics, Inc...announced today that its scientific leadership will present at the following upcoming conferences: iPSC-Derived Cell Therapies Summit (Virtual Event)...Antibody Engineering & Therapeutics Conference (San Diego, California)."

Clinical data • Oncology • Solid Tumor

Cytovia Therapeutics Opens Boston R&D Center of Excellence and Announces cGMP Manufacturing Facility, Aiming to Start Clinical Trials for its Gene-Edited iPSC CAR-NK Cells by 2022 (GlobeNewswire) - "Cytovia Therapeutics, Inc...announced today two agreements for R&D and manufacturing operations in Massachusetts and Puerto Rico that will accelerate the company’s Universal iPSC NK cells towards clinical trials beginning in Q4 2021 and gene-edited iPSC CAR-NK cells by 2022...Cytovia’s first cell product is scheduled to be in the clinic in 2021 with up to three additional CAR-NK cell products following in 2022."

Clinical • Oncology

Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells (GlobeNewswire) - "Cytovia Therapeutics, Inc...and Cellectis...announced today that they have entered into a strategic research and development collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells...'We look forward to leveraging Cellectis’ insights and experience to help move Cytovia’s CAR-NKs into clinical trials by 2022.'"

Licensing / partnership • New trial • Oncology • Solid Tumor

Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for the Treatment of Cancer (GlobeNewswire) - "Cytovia Therapeutics...and the New York Stem Cell Foundation (NYSCF) Research institute today announced the filing of a provisional patent application with the U.S. Patent & Trademark Office (USPTO) for the differentiation of Natural Killer (NK) cells from induced pluripotent stem cells (iPSCs)...Cytovia and NYSCF are also collaborating on the process development of Good Manufacturing Practices (GMP) of iPSC NK and CAR-NK cells with the potential to file additional patents on the engineering, expansion and GMP manufacturing processes of iPSC NK cells to treat cancer....'Cytovia plans to initiate first clinical trials with iPSC NK-cells in 2021.'"

Clinical • New trial • Patent • Oncology